Soluna (NASDAQ:SLNH) versus Predictive Oncology (NASDAQ:POAI) Critical Review

Predictive Oncology (NASDAQ:POAI) and Soluna (NASDAQ:SLNH) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Profitability

This table compares Predictive Oncology and Soluna’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Soluna	-182.16%	-52.19%	-32.17%

Volatility and Risk

Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Soluna has a beta of 5.07, indicating that its share price is 407% more volatile than the S&P 500.

Insider and Institutional Ownership

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 23.2% of Soluna shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 15.5% of Soluna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Predictive Oncology and Soluna, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1	0	0	0	1.00
Soluna	1	1	1	0	2.00

Soluna has a consensus target price of $4.00, suggesting a potential upside of 233.33%. Given Soluna’s stronger consensus rating and higher probable upside, analysts plainly believe Soluna is more favorable than Predictive Oncology.

Valuation and Earnings

This table compares Predictive Oncology and Soluna”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66 million	21.76	-$12.66 million	($13.50)	-0.79
Soluna	$42.08 million	7.04	-$53.41 million	($1.12)	-1.07

Predictive Oncology has higher earnings, but lower revenue than Soluna. Soluna is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Soluna beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

About Predictive Oncology

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

About Soluna

Soluna Holdings, Inc. together with its subsidiaries, engages in the mining of cryptocurrency through data centers. It operates through two segments, Cryptocurrency Mining and Data Center Hosting. The company also operates in the blockchain business. In addition, the company develops and builds modular data centers that use for cryptocurrency mining. Further, it provides data center hosting services, including electrical power and network connectivity to cryptocurrency mining customers. The company was formerly known as Mechanical Technology Inc and as changed to Soluna Holdings, Inc. Soluna Holdings, Inc. was incorporated in 1961 and is headquartered in Albany, New York.